This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Extended-delivery anti-VEGF
Beverly Hills, CA
Beverly Hills, California, United States
RECRUITINGWake Forest, NC
Wake Forest, North Carolina, United States
RECRUITINGErie, PA
Erie, Pennsylvania, United States
Incidence and severity of ocular treatment-emergent adverse events (TEAEs)
Time frame: Week 72
Incidence and severity of systemic treatment-emergent adverse events (TEAEs)
Time frame: Week 72
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bellaire, TX
Bellaire, Texas, United States
RECRUITINGMcAllen, TX
McAllen, Texas, United States
RECRUITINGThe Woodlands, TX
The Woodlands, Texas, United States
RECRUITING